Area of research
Immunology · Oncology
Research interest
Research interests include CAR-T cell therapy research, Immune Cell Function and Interaction, Immunotherapy and Immune Responses, and RNA Interference and Gene Delivery.
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody
Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens
Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial
Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide
Impact of p53 Knock-Down on T-Cell Proliferation and T-Cell Mediated Cytotoxicity Against AML Cell Lines Mediated By a CD33 Specific BiTE® Antibody Construct
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells
The Ratio of Costimulatory Vs Coinhibitory Molecules on AML Cells Determines the CD33-BiTE® Mediated T-Cell Response
Diagnosis of <scp>CLL</scp> revisited: increased specificity by a modified five‐marker scoring system including <scp>CD</scp>200
Induction of Antigen-Specific T-Cell Responses through Dendritic Cell Vaccination in AML: Results of a Phase I/II Trial and Ex Vivo Enhancement By Checkpoint Blockade
Steroids Abrogate BiTE® Antibody Construct-Mediated Cytotoxicity in Primary AML Cells
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330